SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-161592
Filing Date
2024-06-14
Accepted
2024-06-14 16:05:53
Documents
16
Period of Report
2024-06-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d826178d8k.htm   iXBRL 8-K 36658
2 EX-10.1 d826178dex101.htm EX-10.1 58904
3 EX-99.1 d826178dex991.htm EX-99.1 66655
4 EX-99.2 d826178dex992.htm EX-99.2 79270
  Complete submission text file 0001193125-24-161592.txt   424229

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20240611.xsd EX-101.SCH 2860
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20240611_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20240611_pre.xml EX-101.PRE 11268
19 EXTRACTED XBRL INSTANCE DOCUMENT d826178d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 241044729
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)